Holdings of Invesco Nasdaq Biotechnology ETF
Invesco Exchange-Traded Fund Trust II · Original filing · Compare with another fund · Report an error
- Net assets
- 75.7M $ including 75.6M $ in equities, 99.9 %
- Positions
- 261 in 18 countries
- Top ten
- 46.7 % of net assets
- Filed on
- Feb 28, 2026
Portfolio shape
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 101 | Pharvaris NV | 3,591 | 101.9K $ | 0.13 % |
| 102 | Vericel Corp | 2,833 | 101.1K $ | 0.13 % |
| 103 | Relay Therapeutics Inc | 9,680 | 99.3K $ | 0.13 % |
| 104 | Enliven Therapeutics Inc | 3,328 | 98.8K $ | 0.13 % |
| 105 | Tyra Biosciences Inc | 2,966 | 98.8K $ | 0.13 % |
| 106 | Agios Pharmaceuticals Inc | 3,239 | 97.9K $ | 0.13 % |
| 107 | Sarepta Therapeutics Inc | 5,837 | 97.8K $ | 0.13 % |
| 108 | Zymeworks Inc | 4,184 | 97.4K $ | 0.13 % |
| 109 | Definium Therapeutics Inc | 5,503 | 96K $ | 0.13 % |
| 110 | Innoviva Inc | 4,181 | 96K $ | 0.13 % |
| 111 | Genmab A/S | 3,245 | 95.5K $ | 0.13 % |
| 112 | ANI Pharmaceuticals Inc | 1,263 | 93.3K $ | 0.12 % |
| 113 | Amylyx Pharmaceuticals Inc | 6,115 | 92.8K $ | 0.12 % |
| 114 | Oruka Therapeutics Inc | 2,692 | 92.6K $ | 0.12 % |
| 115 | Novavax Inc | 9,091 | 92.2K $ | 0.12 % |
| 116 | Sionna Therapeutics Inc | 2,514 | 91.9K $ | 0.12 % |
| 117 | Harmony Biosciences Holdings Inc | 3,206 | 91.5K $ | 0.12 % |
| 118 | Nurix Therapeutics Inc | 5,681 | 90.7K $ | 0.12 % |
| 119 | RAPT THERAPEUTICS INC | 1,551 | 89.9K $ | 0.12 % |
| 120 | LEGEND BIOTECH CORP | 4,707 | 89.4K $ | 0.12 % |
| 121 | Ardelyx Inc | 13,580 | 88.9K $ | 0.12 % |
| 122 | Intellia Therapeutics Inc | 6,453 | 88.9K $ | 0.12 % |
| 123 | Novocure Ltd | 6,261 | 85.6K $ | 0.11 % |
| 124 | AnaptysBio Inc | 1,550 | 85.3K $ | 0.11 % |
| 125 | Iovance Biotherapeutics Inc | 22,091 | 85.3K $ | 0.11 % |
| 126 | Trevi Therapeutics Inc | 7,146 | 85.2K $ | 0.11 % |
| 127 | Tango Therapeutics Inc | 7,535 | 83.9K $ | 0.11 % |
| 128 | MBX Biosciences Inc | 2,526 | 82.2K $ | 0.11 % |
| 129 | EyePoint Inc | 4,637 | 81.4K $ | 0.11 % |
| 130 | Kodiak Sciences Inc | 2,951 | 79.1K $ | 0.10 % |
| 131 | Immunocore Holdings PLC | 2,432 | 78.6K $ | 0.10 % |
| 132 | ZENAS BIOPHARMA INC | 2,980 | 78.5K $ | 0.10 % |
| 133 | Rapport Therapeutics Inc | 2,657 | 77.1K $ | 0.10 % |
| 134 | Corvus Pharmaceuticals Inc | 4,177 | 76.3K $ | 0.10 % |
| 135 | Precigen Inc | 19,747 | 74.8K $ | 0.10 % |
| 136 | Collegium Pharmaceutical Inc | 1,776 | 74K $ | 0.10 % |
| 137 | AtaiBeckley Inc | 20,269 | 73.6K $ | 0.10 % |
| 138 | ORIC Pharmaceuticals Inc | 5,451 | 73.3K $ | 0.10 % |
| 139 | Septerna Inc | 2,520 | 73.1K $ | 0.10 % |
| 140 | Vir Biotechnology Inc | 7,785 | 70.8K $ | 0.09 % |
| 141 | Alvotech SA | 17,492 | 69.8K $ | 0.09 % |
| 142 | Taysha Gene Therapies Inc | 15,289 | 69.3K $ | 0.09 % |
| 143 | Savara Inc | 11,348 | 68.3K $ | 0.09 % |
| 144 | Monte Rosa Therapeutics Inc | 3,640 | 64.6K $ | 0.09 % |
| 145 | Sana Biotechnology Inc | 14,886 | 62.7K $ | 0.08 % |
| 146 | Grifols SA | 6,813 | 62K $ | 0.08 % |
| 147 | Phibro Animal Health Corp | 1,124 | 61.4K $ | 0.08 % |
| 148 | Day One Biopharmaceuticals Inc | 5,740 | 60.8K $ | 0.08 % |
| 149 | AbCellera Biologics Inc | 16,724 | 60.4K $ | 0.08 % |
| 150 | Geron Corp | 35,647 | 59.9K $ | 0.08 % |
| 151 | Inhibrx Biosciences Inc | 807 | 59.8K $ | 0.08 % |
| 152 | UroGen Pharma Ltd | 2,613 | 56.7K $ | 0.07 % |
| 153 | Xeris Biopharma Holdings Inc | 9,253 | 56.6K $ | 0.07 % |
| 154 | MannKind Corp | 17,136 | 56.2K $ | 0.07 % |
| 155 | Ventyx Biosciences Inc | 3,977 | 55.6K $ | 0.07 % |
| 156 | Fortrea Holdings Inc | 5,176 | 55.5K $ | 0.07 % |
| 157 | uniQure NV | 3,468 | 54.2K $ | 0.07 % |
| 158 | ArriVent Biopharma Inc | 2,313 | 53.1K $ | 0.07 % |
| 159 | Pacira BioSciences Inc | 2,398 | 52.5K $ | 0.07 % |
| 160 | Amphastar Pharmaceuticals Inc | 2,574 | 52.1K $ | 0.07 % |
| 161 | Theravance Biopharma Inc | 2,837 | 51.8K $ | 0.07 % |
| 162 | Bicara Therapeutics Inc | 3,072 | 51.5K $ | 0.07 % |
| 163 | Cullinan Therapeutics Inc | 3,316 | 51.4K $ | 0.07 % |
| 164 | GH RESEARCH PLC | 3,456 | 51.3K $ | 0.07 % |
| 165 | ARS Pharmaceuticals Inc | 5,518 | 51.2K $ | 0.07 % |
| 166 | Xencor Inc | 3,980 | 50.8K $ | 0.07 % |
| 167 | CytomX Therapeutics Inc | 9,460 | 50.8K $ | 0.07 % |
| 168 | Arbutus Biopharma Corp | 10,743 | 50.1K $ | 0.07 % |
| 169 | Phathom Pharmaceuticals Inc | 3,967 | 49.8K $ | 0.07 % |
| 170 | Castle Biosciences Inc | 1,619 | 47.9K $ | 0.06 % |
| 171 | Arvinas Inc | 3,599 | 47.8K $ | 0.06 % |
| 172 | Omeros Corp | 3,957 | 47.7K $ | 0.06 % |
| 173 | Prime Medicine Inc | 10,067 | 46.5K $ | 0.06 % |
| 174 | KalVista Pharmaceuticals Inc | 2,831 | 46.1K $ | 0.06 % |
| 175 | Janux Therapeutics Inc | 3,365 | 45.8K $ | 0.06 % |
| 176 | Annexon Inc | 8,089 | 45.3K $ | 0.06 % |
| 177 | Personalis Inc | 4,964 | 45K $ | 0.06 % |
| 178 | BioAge Labs Inc | 2,018 | 44.9K $ | 0.06 % |
| 179 | Esperion Therapeutics Inc | 13,354 | 44.7K $ | 0.06 % |
| 180 | Mesoblast Ltd. | 2,721 | 43.1K $ | 0.06 % |
| 181 | Kura Oncology Inc | 4,878 | 42.6K $ | 0.06 % |
| 182 | ZAI LAB LTD | 2,174 | 41.8K $ | 0.06 % |
| 183 | Compass Pathways plc | 5,259 | 36.3K $ | 0.05 % |
| 184 | Rigel Pharmaceuticals Inc | 1,019 | 35.4K $ | 0.05 % |
| 185 | Allogene Therapeutics Inc | 12,556 | 34.9K $ | 0.05 % |
| 186 | MeiraGTx Holdings plc | 4,490 | 33.9K $ | 0.04 % |
| 187 | Replimune Group Inc | 4,391 | 33.6K $ | 0.04 % |
| 188 | Design Therapeutics Inc | 3,177 | 33.2K $ | 0.04 % |
| 189 | Neumora Therapeutics Inc | 9,348 | 32.6K $ | 0.04 % |
| 190 | CorMedix Inc | 4,414 | 31.5K $ | 0.04 % |
| 191 | Ironwood Pharmaceuticals Inc | 9,099 | 31.1K $ | 0.04 % |
| 192 | 4D Molecular Therapeutics Inc | 3,185 | 30.8K $ | 0.04 % |
| 193 | Rocket Pharmaceuticals Inc | 6,041 | 30.3K $ | 0.04 % |
| 194 | Vanda Pharmaceuticals Inc | 3,317 | 29.6K $ | 0.04 % |
| 195 | Lexeo Therapeutics Inc | 4,094 | 29.4K $ | 0.04 % |
| 196 | Lyell Immunopharma Inc | 1,207 | 29K $ | 0.04 % |
| 197 | Maravai LifeSciences Holdings Inc | 8,103 | 28.8K $ | 0.04 % |
| 198 | Pacific Biosciences of California Inc | 16,852 | 28.3K $ | 0.04 % |
| 199 | Zevra Therapeutics Inc | 3,142 | 28.1K $ | 0.04 % |
| 200 | Kamada Ltd | 3,210 | 27.9K $ | 0.04 % |
Sector breakdown
- Health care 53.0 %
- Unattributed 47.0 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- United States 89.4 %
- Netherlands 2.2 %
- Bermuda 1.5 %
- France 1.5 %
- Ireland 1.3 %
- Denmark 1.2 %
- Germany 0.8 %
- Canada 0.6 %
- Switzerland 0.5 %
- Cayman Islands 0.3 %
- Singapore 0.2 %
- Jersey 0.1 %
- Other countries 0.4 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | United States | 225 | 67.7M $ | 89.44 % |
| 2 | Netherlands | 4 | 1.6M $ | 2.18 % |
| 3 | Bermuda | 1 | 1.1M $ | 1.51 % |
| 4 | France | 2 | 1.1M $ | 1.50 % |
| 5 | Ireland | 4 | 1M $ | 1.34 % |
| 6 | Denmark | 2 | 906.7K $ | 1.20 % |
| 7 | Germany | 1 | 631.2K $ | 0.83 % |
| 8 | Canada | 4 | 450.4K $ | 0.60 % |
| 9 | Switzerland | 2 | 342.2K $ | 0.45 % |
| 10 | Cayman Islands | 5 | 193.3K $ | 0.26 % |
| 11 | Singapore | 1 | 130.3K $ | 0.17 % |
| 12 | Jersey | 1 | 85.6K $ | 0.11 % |
Cite this page
Titelia. "Holdings of Invesco Nasdaq Biotechnology ETF". https://titelia.com/en/funds/S000072469